FindTrial
Sign In

Investigation on adverse reactions of immunotherapy and secondary infection in tumor patients

Investigation on adverse reactions of immunotherapy and secondary infection in tumor patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500111215
Enrollment
Unknown
Registered
2025-10-28
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

Observation group:None

Sponsors

Shanxi Province Cancer Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Men or women aged 18 or above; (2) Confirmed by histology to have a solid tumor or a blood tumor; (3) Have received at least one dose of ICIs treatment; (4) Organ damage occurred within 6 months after ICIs treatment.

Exclusion criteria

Exclusion criteria: (1) Underage patients; (2) Those with a history of autoimmune diseases or endocrine diseases;

Design outcomes

Primary

MeasureTime frame
Prognostic information;—

Secondary

MeasureTime frame
Clinical index;Vital signs;Immune related examination;Infection-related examination;Metabolic and inflammatory indicators;Organ damage index;Imaging examination results;Severity score;—

Countries

China

Contacts

Public ContactDuan Yan

Shanxi Province Cancer Hospital

sxszlyyzzyx@163.com+86 139 9429 9045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026